| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | Compositions, methods and devices for forming implants from injected liquids | US15704792 | 2017-09-14 | US10123980B2 | 2018-11-13 | Chandrashekhar P. Pathak |
| A method of forming an implant in the tissue can include: providing an injectable composition having a neat liquid carrier, wherein the neat liquid carrier is substantially liquid at room temperature and/or about body temperature; and injecting the neat liquid solution into the tissue at the rate of 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per needle per injection. The neat liquid carrier can be polymeric or non-polymeric. The neat liquid carrier can be biodegradable. The neat liquid carrier can include a viscosity-modifying agent. The injecting can form an implant with area greater than or equal to 5 mm2. The neat liquid carrier can be injected at a depth of 10 microns to 5 mm. The neat liquid solution can include a drug or other agent. | ||||||
| 62 | METHOD OF TREATING OR PREVENTING STROKE | US15527066 | 2015-11-17 | US20180237513A1 | 2018-08-23 | Ulf ERIKSSON; Ingrid NILSSON; Daniel LAWRENCE; Enming Joe SU |
| A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling | ||||||
| 63 | A NOVEL PURIFICATION PROCESS FOR ISOLATION AND COMMERCIAL PRODUCTION OF RECOMBINANT TNK-TPA TENECTEPLASE | US15505837 | 2015-10-19 | US20180223270A1 | 2018-08-09 | Arjun RAGHUWANSHI; Shrawan SINGH KUMAR; Ankit KUMAR; Mihir SAHOO RANJAN; Sanjay SINGH |
| The present invention relates to a novel process of isolating and purifying tissue plasminogen activator and its variants more specifically TNK-tPA from CHO cells and describes an industrially applicable, simple, cost effective, robust and highly efficient process of TNK-tPA purification. | ||||||
| 64 | DRUG REGIMEN FOR TREATMENT OF CEREBRAL ISCHEMIA | US15859075 | 2017-12-29 | US20180185475A1 | 2018-07-05 | Lawrence M. KAUVAR; Damir JANIGRO |
| Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity. | ||||||
| 65 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF AN ENZYME TO A SUBJECT'S AIRWAY | US15571529 | 2016-05-06 | US20180140547A1 | 2018-05-24 | Robert O. WILLIAMS, III; Steven IDELL |
| Methods and composition for delivery of enzymes to a subject's airway. In some aspects, nebulized composition of enzymes, such as plasminogen activators are provided. In further aspects perfluorocarbon compositions comprising enzymes, such as plasminogen activators are provided. Compositions may, in some aspects, be used for the treatment of lung infections or acute lung injury, such as inhalational smoke induced acute lung injury (ISALI). | ||||||
| 66 | COMPOSITIONS, METHODS AND DEVICES FOR FORMING IMPLANTS FROM INJECTED LIQUIDS | US15704792 | 2017-09-14 | US20180000756A1 | 2018-01-04 | Chandrashekhar P. Pathak |
| A method of forming an implant in the tissue can include: providing an injectable composition having a neat liquid carrier, wherein the neat liquid carrier is substantially liquid at room temperature and/or about body temperature; and injecting the neat liquid solution into the tissue at the rate of 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per needle per injection. The neat liquid carrier can be polymeric or non-polymeric. The neat liquid carrier can be biodegradable. The neat liquid carrier can include a viscosity-modifying agent. The injecting can form an implant with area greater than or equal to 5 mm2. The neat liquid carrier can be injected at a depth of 10 microns to 5 mm. The neat liquid solution can include a drug or other agent. | ||||||
| 67 | Pharmaceutical compositions and methods for digesting atherosclerotic plaques | US14326904 | 2014-07-09 | US09707281B2 | 2017-07-18 | Melina R. Kibbe; Guillermo A. Ameer; Vinit N. Varu |
| Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator. | ||||||
| 68 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | US14972268 | 2015-12-17 | US20160194623A1 | 2016-07-07 | Denis VIVIEN; Jerome PARCQ |
| The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases. | ||||||
| 69 | Mutated tissue plasminogen activators and uses thereof | US14342164 | 2012-09-07 | US09249406B2 | 2016-02-02 | Denis Vivien; Jerome Parcq |
| The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases. | ||||||
| 70 | METHODS AND COMPOSITIONS FOR IMPROVING HEMOSTASIS | US14793730 | 2015-07-07 | US20160000823A1 | 2016-01-07 | R. Martin EMANUELE; Debra Hoppensteadt; Jawed Fareed |
| Provided are methods and uses of polyoxyethylene/polyoxypropylene copolymers (poloxamers) for treating bleeding and hemorrhage in animals, including human or veterinary subjects, and thus, treating hemostatic dysfunction, resulting from, for example, drug, disease-, trauma- or surgical-induced bleeding. Polyoxyethylene/polyoxypropylene copolymers improve hemostasis and aid in the control of bleeding. Methods for treating strokes using the polyoxyethylene/polyoxypropylene copolymers also are provided. Devices, products and compositions for treating or preventing hemostatic dysfunction are provided. | ||||||
| 71 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | US14721761 | 2015-05-26 | US20150343080A1 | 2015-12-03 | Shawn DeFrees; David A. Zopf; Robert J. Bayer; David James Hakes; Caryn L. Bowe; Xi Chen |
| The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | ||||||
| 72 | Compositions and Methods for Treating Stroke | US14433172 | 2013-10-17 | US20150238502A1 | 2015-08-27 | David Andrew Decker; Keith Pennypacker |
| Provided herein is a method of treating a subject believed to have suffered a stroke. This method comprises administering to the subject therapeutically effective amount of a composition comprising conivaptan or an active derivative, stereoisomer, pro-drug, or pharmaceutically acceptable salt thereof. | ||||||
| 73 | CHIMERIC NEUREGULINS AND METHOD OF MAKING AND USE THEREOF | US13865812 | 2013-04-18 | US20140227247A2 | 2014-08-14 | Byron D. FORD |
| Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin. | ||||||
| 74 | Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease | US14140609 | 2013-12-26 | US20140186423A1 | 2014-07-03 | Mathew Gelfand |
| The present invention relates to a method and device for treating patients with a Protein Misfolding Disease by chronically administering an effective dose of a thrombolytic reagent and/or a thrombolytic reagent regulator over an intermittent period of time. The thrombolytic reagents degrade the misfolded proteins that accumulate and that can become toxic in such patients. The thrombolytic reagent regulators increase the catalytic efficiency of the thrombolytic reagents to reduce the amount of thrombolytic reagents necessary for an effective dose. The administration is administered transdermally via a transdermal patch that is equipped with an ultrasound transducer for enhancing the penetration of the thrombolytic reagent and thrombolytic reagent regulator into the bloodstream of a patient by increasing the permeability of the patient's skin. | ||||||
| 75 | Chimeric neuregulins and method of making and use thereof | US13627555 | 2012-09-26 | US08748131B2 | 2014-06-10 | Byron D. Ford |
| Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin. | ||||||
| 76 | CONTROLLING MAGNETIC NANOPARTICLES TO INCREASE VASCULAR FLOW | US14020173 | 2013-09-06 | US20140135564A1 | 2014-05-15 | Francis M. Creighton |
| Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. | ||||||
| 77 | CHIMERIC NEUREGULINS AND METHOD OF MAKING AND USE THEREOF | US13865812 | 2013-04-18 | US20140086897A1 | 2014-03-27 | Byron D. FORD |
| Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin. | ||||||
| 78 | Use of matrix metalloproteinase-10 (MMP-10) for thrombolytic treatments | US12861357 | 2010-08-23 | US08541370B2 | 2013-09-24 | Josune Orbe Lopategui; Jose Antonio Rodriguez Garcia; Jose Antonio Paramo Fernandez; Rosario Serrano Vargas |
| The present invention relates to the use of matrix metalloproteinase MMP-10 in the preparation of a pharmaceutical composition useful for thrombolytic therapy, it also being possible for said composition to contain a plasminogen activator. Additionally, the present invention relates to said pharmaceutical composition for the treatment of thrombotic disorders. | ||||||
| 79 | NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE | US13370706 | 2012-02-10 | US20130039902A1 | 2013-02-14 | Mariola Sohngen; Wolfgang Sohngen; Wolf-Dieter Schleuning; Robert Medcalf |
| The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans. | ||||||
| 80 | DEVICES FOR CONTROLLING MAGNETIC NANOPARTICLES TO TREAT FLUID OBSTRUCTIONS | US13505447 | 2010-11-02 | US20120310034A1 | 2012-12-06 | Francis M. Creighton; Rogers C. Ritter |
| The present invention relates to a system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator. In one aspect, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. Examples of vascular occlusions targeted by the system include, but are not limited to, atherosclerotic plaques, including fibrous caps, fatty buildup, coronary occlusions, arterial stenosis, restenosis, vein thrombi, arterial thrombi, cerebral thrombi, embolisms, hemorrhages, other blood clots, and very small vessels. | ||||||
QQ群二维码
意见反馈
意见反馈